TITLE

Pipeline

PUB. DATE
May 2009
SOURCE
Pharmaceutical Representative;May2009, Vol. 39 Issue 5, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information related to clinical trials in the U.S. in 2009. OPKO Health Inc. has terminated the Phase III trial of its bevasiranib because the trial cannot meet its primary end point. GlaxoSmithKline (GSK) and Synta Pharmaceutical Corp. has suspended their Phase III trial of elesclomol because of safety concerns. Vertex Pharmaceuticals Inc. has started the Phase IIa clinical trial for its VX-809, a drug for patients with cystic fibrosis.
ACCESSION #
39258117

 

Related Articles

  • Cystic fibrosis combo treatment meets phase 3 endpoints.  // Nature Biotechnology;Aug2014, Vol. 32 Issue 8, p709 

    The article reports on phase 3 clinical trials of Vertex Pharmaceuticals' Kalydeco plus Lumacaftor combination treatment for cystic fibrosis (CF) and mentions that the drug improved the lung function of the patients during the trials as of August 2014.

  • Vertex Initiates Phase III Studies of Cystic Fibrosis Drug VX-770. Hollingsworth, Catherine // BioWorld Today;5/28/2009, Vol. 20 Issue 101, p1 

    The article reports on the launch of Phase III studies of cystic fibrosis drug candidate VX-770 from Vertex Pharmaceuticals Inc. Pipe Jaffray & Co. senior research analyst Edward Tenthoff said that the expected dates for enrolling patients in the trial are achievable. The Cambridge,...

  • Vertex Cystic Fibrosis Results Positive, But No Home Run. Shaffer, Catherine // BioWorld Today;6/10/2011, Vol. 22 Issue 112, p2 

    The article reports on the results of a Phase II trial of a combination of two drugs for cystic fibrosis (CF) by Vertex Pharmaceuticals. Such trial is said to have positive interim results though the results cannot guarantee improved lung function for CF patients just yet. Vertex will commence...

  • Vertex Falls on Corrected CF Results for Kalydeco Combo. Shaffer, Catherine // BioWorld Today;5/30/2012, p1 

    The article reports on the 10 percent decline of the stock price of Vertex Pharmaceuticals Inc. after the release of corrected clinical data for a Phase II trial of Kalydeco (ivacaftor) with VX-809. The trial has revealed that an absolute improvement in lung function was experienced by only 35...

  • Vertex Tweaks Data Presentation, Investors React. Orelli, Brian // BioWorld Insight;7/16/2012, Vol. 20 Issue 29, p2 

    The article focuses on the data presented by Vertex Pharmaceuticals Inc. on the phase II trial of drug combination comprising VX-809 and Kalydeco in treating cystic fibrosis It mentions the release of results of the Phase II trial, the stock fall 16 percent stating that the results were...

  • Vertex: Positive results for cystic fibrosis drug.  // PharmaWatch: Monthly Review;May2008, Vol. 7 Issue 5, p16 

    The article reports the completion of the Phase II trial of VX-770, a novel cystic fibrosis (CF) therapy by Vertex Pharmaceuticals Inc. in the U.S. It states that the results of the trial are encouraging and suggest an approach to traditional reactive management of CF. Meanwhile, Vertex reports...

  • Data from the First Part of a Phase 2 Study Support the Approach of Treating the Most Common Form of Cystic Fibrosis (F508del) by Targeting the Underlying Cause of the Disease With a Combination of KALYDECO (ivacaftor) and VX-809.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p156 

    The article reports on the move of Vertex Pharmaceuticals Inc. to release the result of its Phase 2 study of Kalydeco (ivacaftor) and VX-809 for the treatment of cystic fibrosis (CF) in Anaheim, California. The company reveals that the combination of the two cystic fibrosis transmembrane...

  • Synta's Elesclomol In Pivotal Study In Melanoma Patients. Morrison, Trista // BioWorld Today;11/13/2007, Vol. 18 Issue 221, p1 

    The article discusses the Phase III trial of Synta Pharmaceuticals Corporation's elesclomol drug for patients with metastatic melanoma, in November 2007. Synta has reportedly entered into a deal with GlaxoSmithKline PLC regarding its drug. Evaluation will be conducted at the primary endpoint of...

  • Drug bests cystic-fibrosis mutation. Ledford, Heidi // Nature;2/9/2012, Vol. 482 Issue 7384, p145 

    The article offers information on the clinical trial of Kalydeco, a cystic fibrosis treatment approved by the U.S. Food and Drug Administration (FDA). It mentions that the drug is manufactured by Vertex Pharmaceuticals Inc. and targets a cause of cystic fibrosis rather than the condition's...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics